Analyst Ratings For Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN)
Today, Cantor Fitzgerald raised its price target on Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) to $82.00 per share.
There are 8 Buy Ratings, 1 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) is Buy with a consensus target price of $54.6250 per share, a potential 21.04% upside.
Some recent analyst ratings include
- 3/4/2019-Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) had its Buy ➝ Buy rating reiterated by Needham & Company LLC with a $56.00 price target
- 11/15/2018-Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) had its Outperform rating reiterated by William Blair
- 11/12/2018-Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) has coverage initiated with a Outperform rating and $50.00 price target
- 10/11/2018-Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) had its Buy rating reiterated by Morgan Stanley with a $47.00 price target
- On 3/1/2019 Declan Doogan, Director, sold 50,595 with an average share price of $47.17 per share and the total transaction amounting to $2,386,566.15.
- On 2/27/2019 Declan Doogan, Director, sold 27,045 with an average share price of $45.02 per share and the total transaction amounting to $1,217,565.90.
- On 2/21/2019 Julia P Gregory, Director, sold 12,000 with an average share price of $43.56 per share and the total transaction amounting to $522,720.00.
- On 2/19/2019 Declan Doogan, Director, sold 2,078 with an average share price of $45.48 per share and the total transaction amounting to $94,507.44.
- On 2/13/2019 Declan Doogan, Director, sold 40,000 with an average share price of $44.31 per share and the total transaction amounting to $1,772,400.00.
- On 1/10/2019 John Tilton, Insider, sold 10,500 with an average share price of $37.67 per share and the total transaction amounting to $395,535.00.
- On 6/15/2018 Kimberly Gentile, VP, sold 12,500 with an average share price of $40.02 per share and the total transaction amounting to $500,250.00.
About Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN)
Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops product candidates to treat neurological diseases, including rare disorders. Its lead product candidate is rimegepant, which is in Phase III clinical trials for the acute treatment of migraine. The company also develops trigriluzole, which is in a Phase II/III clinical trial used for the treatment of ataxias with an initial focus on spinocerebellar ataxia; and Phase II/III clinical trial for the treatment of obsessive compulsive disorders, as well as for the treatment of Alzheimer's diseases. In addition, it develops BHV-3500 for the acute treatment and prevention of migraine; BHV-0223 for the treatment of amyotrophic lateral sclerosis, a neurodegenerative disease that affects nerve cells in the brain and spinal cord; and BHV-5000 for the treatment of symptoms associated with Rett syndrome, such as breathing irregularities. The company was founded in 2013 and is based in New Haven, Connecticut. Biohaven Pharmaceutical Holding Company Ltd. is a subsidiary of Portage Biotech Inc.
Recent Trading Activity for Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN)
Shares of Biohaven Pharmaceutical Holding Co Ltd closed the previous trading session at 45.01 −2.50 5.26% with 47.71 shares trading hands.
